Xinhua Pharmaceutical issued a number of executive departure announcements
on the evening of September 19.
Among them, He Tongqing applied to resign as deputy general manager due to work adjustments, and Wang Xiaolong and Du Deqing applied to resign as deputy general managers due to job changes
.
On the same day, Liu Xuesong and Kou Zuxing were appointed as deputy general managers
of the company.
Xinhua Pharmaceutical has experienced frequent
executive changes during the year.
On the same day, in addition to the departure of 3 deputy general managers, Chairman Zhang Daiming resigned
due to age.
In addition, on the evening of July 1, Xinhua Pharmaceutical issued an announcement that Mr.
Du Deping applied to resign from all positions of the company's directors, general managers, professional committees under the board of directors and subsidiaries of the company due to job changes
.
According to the annual report, its annual salary in 2021 is 1.
396 million yuan
.
According to the data, Xinhua Pharmaceutical is mainly engaged in the development, manufacture and sales of chemical raw materials, preparations and chemical products, the main products are antipyretic and analgesic APIs, tablets, injections, capsules, pharmaceutical intermediates
.
Since the beginning of this year, Xinhua Pharmaceutical has attracted much attention when the company Xinhua Pharmaceutical issued an announcement at the end of April that it signed a "Strategic Cooperation Agreement" with Real Biologics, and Real Biologics agreed that Xinhua Pharmaceutical was the manufacturer and distributor
of its products such as azivudin in China and other countries with mutual consent.
Affected by this news, Xinhua Pharmaceutical's stock price rose all the way, once touching a high price of 40.
7 yuan / share, and the stock price rose by more than 150%.
Recently, the list of national medical insurance drug catalogues adjusted through the preliminary formal review has the figure
of azivudin tablets.
In the afternoon of September 7, affected by this news, Xinhua Pharmaceutical rose more than 1% intraday, and related concept stocks such as Tuoxin Pharmaceutical and China Resources Shuanghe also rose
.
It is worth mentioning that the change of deputy general managers of pharmaceutical companies seems to have become the norm
.
It is worth mentioning that the change of deputy general managers of pharmaceutical companies seems to have become the norm
.
One day later, First Pharmaceutical issued an announcement that the company deliberated and passed the "Proposal on Appointing Ms.
Lin Huayan as the Deputy General Manager of the Company", and the Company appointed Ms.
Lin Huayan as the Deputy General Manager
of the Company.
Previously, on June 23, the Company agreed that the Board of Directors of the Company would appoint Ms.
Lin Huayan as the Secretary of the Board of Directors and Chief Financial Officer of the
Company.
On the same day, Mr.
Zhang Haibo was also appointed as the deputy general manager of the company (presiding over the work); Mr.
Fang Yuan is the Deputy General Manager
of the Company.
According to statistics, since August this year alone, a large number of deputy general managers of pharmaceutical companies have left, including Mr.
Yan Xiaojia, deputy general manager and secretary of the board of directors of Yihua Health, Mr.
Xiao Qiang, deputy general manager of Harbin Pharmaceutical Group, and Mr
.
Fang Qinhu, deputy general manager of Si Litai.
From the perspective of the reasons for leaving, personal reasons account for the main part, but also partly because of job adjustments and changes
.
Of course, since August, there have also been some new deputy general managers of pharmaceutical companies, including Mr.
Peng Jun as the deputy general manager of Sichuang Medical Hui, Ms.
Ma Lina as the deputy general manager of Huiyu Pharmaceutical, and Xinhua Medical appointed Mr.
Zhu Qingguo and Mr.
Wang Jianqiang as the deputy general managers of the
company.
Behind the frequent changes in the deputy general managers of pharmaceutical companies, the industry believes that the changes in the pharmaceutical industry are intensifying
.
In recent years, affected by policies such as the normalization of collection and the adjustment of medical insurance, the profits of pharmaceutical companies have generally been under pressure, and the task of transformation and upgrading is urgent, in this context, the relevant business adjustments have accelerated, and the accompanying personnel changes including executives have become more frequent
.
At the same time, the expansion of demand for high-level visits by many pharmaceutical companies has also intensified the flow of executives
.
